Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer
- PMID: 27203739
- PMCID: PMC5130041
- DOI: 10.18632/oncotarget.9442
Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer
Abstract
This study aims to compare the radiobiological response of two stereotactic body radiotherapy (SBRT) schedules for patients with stage I peripheral non-small cell lung cancer (NSCLC) using radiobiological modeling methods. Volumetric modulated arc therapy (VMAT)-based SBRT plans were designed using two dose schedules of 1 × 34 Gy (34 Gy in 1 fraction) and 4 × 12 Gy (48 Gy in 4 fractions) for 19 patients diagnosed with primary stage I NSCLC. Dose to the gross target volume (GTV), planning target volume (PTV), lung and chest wall (CW) were converted to biologically equivalent dose in 2 Gy fraction (EQD2) for comparison. Five different radiobiological models were employed to predict the tumor control probability (TCP) value. Three additional models were utilized to estimate the normal tissue complication probability (NTCP) value for the lung and the modified equivalent uniform dose (mEUD) value to the CW. Our result indicates that the 1 × 34 Gy dose schedule provided a higher EQD2 dose to the tumor, lung and CW. Radiobiological modeling revealed that the TCP value for the tumor, NTCP value for the lung and mEUD value for the CW were 7.4% (in absolute value), 7.2% (in absolute value) and 71.8% (in relative value) higher on average, respectively, using the 1 × 34 Gy dose schedule.
Keywords: dose schedule; non-small cell lung cancer; radiobiological modeling; stereotactic body radiotherapy.
Conflict of interest statement
No conflicts of interest from all participating authors.
Figures



Similar articles
-
Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy.Sci Rep. 2015 Dec 11;5:18010. doi: 10.1038/srep18010. Sci Rep. 2015. PMID: 26657569 Free PMC article.
-
Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans.Radiat Oncol. 2016 Jan 22;11:10. doi: 10.1186/s13014-015-0578-2. Radiat Oncol. 2016. PMID: 26800883 Free PMC article.
-
Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.Radiat Oncol. 2019 Jun 20;14(1):111. doi: 10.1186/s13014-019-1318-9. Radiat Oncol. 2019. PMID: 31221159 Free PMC article.
-
Tumor control probability modeling for stereotactic body radiation therapy of early-stage lung cancer using multiple bio-physical models.Radiother Oncol. 2017 Feb;122(2):286-294. doi: 10.1016/j.radonc.2016.11.006. Epub 2016 Nov 18. Radiother Oncol. 2017. PMID: 27871671 Free PMC article. Review.
-
Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):227-236. doi: 10.1016/j.ijrobp.2020.08.014. Epub 2020 Sep 6. Int J Radiat Oncol Biol Phys. 2021. PMID: 32900561 Free PMC article.
References
-
- Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;66:117–125. - PubMed
-
- Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27:3290–3296. - PubMed
-
- Solda F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol. 2013;109:1–7. - PubMed
-
- Zheng X, Schipper M, Kidwell K, Lin J, Reddy R, Ren Y, Chang A, Lv F, Orringer M, Spring Kong FM. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys. 2014;90:603–611. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical